SCHEMBL10969002

SCHEMBL10969002

O=Cc1nnc(-c2ccccc2)o1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.61
RAB9A P51151 8/20 0.61
SMN1; SMN2 Q16637 6/20 0.61
HPGD P15428 6/20 0.54
KDM4E B2RXH2 2/20 0.54
NOTUM Q6P988 4/20 0.52
ATAD2 Q6PL18 1/20 0.52
POLB P06746 1/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
TSHR P16473 1/20 0.50
GPR55 Q9Y2T6 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
PTPN1 P18031 1/20 0.49
ALDH1A1 P00352 2/20 0.48
GLA P06280 1/20 0.48
MAPT P10636 1/20 0.48
ALOX15 P16050 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14562591 0.82 PKM (0.63) NPC1RAB9ASMN1; SMN2HPGDKDM4E
SCHEMBL4523089 0.81 NPC1 (0.70) NPC1RAB9ASMN1; SMN2HPGDKDM4E
SCHEMBL28794403 0.81 NPC1 (0.64) NPC1RAB9ASMN1; SMN2KDM4ENOTUM
SCHEMBL27851473 0.81 RAB9A (0.55) NPC1RAB9ASMN1; SMN2HPGDKDM4E
SCHEMBL14562541 0.80 RAB9A (0.55) NPC1RAB9ASMN1; SMN2HPGDKDM4E
SCHEMBL28859116 0.80 NPC1 (0.61) NPC1RAB9ASMN1; SMN2HPGDKDM4E
SCHEMBL11550310 0.78 NPC1 (0.65) NPC1RAB9ASMN1; SMN2HPGDKDM4E
SCHEMBL46426 0.78 NPC1 (1.00) NPC1RAB9ASMN1; SMN2HPGDKDM4E
SCHEMBL6568301 0.77 NPC1 (0.79) NPC1RAB9ASMN1; SMN2HPGDKDM4E
SCHEMBL31595791 0.77 NPC1 (0.51) NPC1RAB9ASMN1; SMN2HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424870-B1 Therapeutic agents 713 ASTRAZENECA AB (SE) 2015-12-16 EP claimed
CN-103936751-A Compound, preparation method and application thereof, and pharmaceutical composition having the same ASTRAZENECA AB 2014-07-23 CN claimed
CN-102459279-B Therapeutic agents 713 ASTRAZENECA AB 2014-06-25 CN claimed
CN-103857682-A Azetidine derivatives for treatment of melanin related disorders ASTRAZENECA AB 2014-06-11 CN claimed
CN-103209979-A Therapeutic agent 976 ASTRAZENECA AB 2013-07-17 CN claimed
CN-102459279-A Therapeutic agents 713 ASTRAZENECA AB 2012-05-16 CN claimed
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 EP disclosed
US-20250171438-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. 2025-05-29 US disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 EP disclosed
EP-2558577-B1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION AS (DK) 2018-12-12 EP disclosed
CN-102459279-A Therapeutic agents 713 ASTRAZENECA AB 2012-05-16 CN disclosed
CN-101563337-A Indole compounds MICROBIA INC (US) 2009-10-21 CN disclosed
US-20070049594-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-03-01 US disclosed
EP-0041675-B1 4-HALOGEN-5-(TRICHLOROMETHYL-PHENYL)-OXAZOLE DERIVATIVES, PROCESS FOR PREPARING THEM AND RADIATION-SENSITIVE COMPOSITIONS CONTAINING THEM HOECHST AKTIENGESELLSCHAFT (DE) 1985-12-11 EP disclosed
US-4446217-A Electrophotographic photosensitive member having a hydrazone containing layer CANON KABUSHIKI KAISHA (JP) 1984-05-01 US disclosed
US-4371607-A 4-Halogeno-5-(halogenomethyl-phenyl)-oxazole derivatives, a process for the preparation thereof, and radiation-sensitive compositions containing these derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1983-02-01 US disclosed
EP-0041675-A2 4-Halogen-5-(trichloromethyl-phenyl)-oxazole derivatives, process for preparing them and radiation-sensitive compositions containing them HOECHST AKTIENGESELLSCHAFT (DE) 1981-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049594-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE NPC1 37/4885RAB9A 512/4885SMN1; SMN2 3350/4885
US-20250171438-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 NPC1 3526/4885RAB9A 1335/4885SMN1; SMN2 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.